Cargando…
Cytochrome P450 1B1 inhibition suppresses tumorigenicity of prostate cancer via caspase-1 activation
Cytochrome P450 1B1 (CYP1B1) is recognized as a universal tumor biomarker and a feasible therapeutic target due to its specific overexpression in cancer tissues. Despite its up-regulation in prostate cancer (PCa), biological significance and clinicopathological features of CYP1B1 are still elusive....
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503597/ https://www.ncbi.nlm.nih.gov/pubmed/28388569 http://dx.doi.org/10.18632/oncotarget.16598 |